Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies — Live Feedhttps://www.live-feeds.com/feed/eli-lilly-inks-2-88b-merida-buyout-for-autoimmune-drugs-against-rogue-antibodiesContinuously updated, source-cited coverage. Eli Lilly acquires Merida Biosciences for up to $2.88 billionhttps://www.live-feeds.com/feed/eli-lilly-inks-2-88b-merida-buyout-for-autoimmune-drugs-against-rogue-antibodieshttps://www.live-feeds.com/feed/eli-lilly-inks-2-88b-merida-buyout-for-autoimmune-drugs-against-rogue-antibodies#u54166Wed, 02 Sep 2026 00:41:00 +0000Eli Lilly is purchasing Massachusetts-based Merida Biosciences to expand its autoimmune drug pipeline. The deal is valued at approximately $2.88 billion, though some reports cite figures up to $2.9 billion or as low as $2.875 billion. Merida specializes in immunology and develops drugs targeting rogue antibodies. This acquisition marks a significant investment in the autoimmune sector and continues Lilly's growth strategy in the biotechnology space.Why it mattersThe acquisition strengthens Lilly's portfolio of immune-related therapies. It also increases the company's presence in